Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 406

1.

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.

Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM.

Leuk Lymphoma. 2019 Sep 13:1-11. doi: 10.1080/10428194.2019.1663419. [Epub ahead of print]

PMID:
31517559
2.

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.

Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, Maurer MJ, Slager SL, Nowakowski GS, Habermann TM, Witzig TE, Link BK, Ansell SM, Cerhan JR, Novak AJ.

Blood Cancer J. 2019 Aug 30;9(9):73. doi: 10.1038/s41408-019-0233-5.

3.

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.

Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P.

Br J Haematol. 2019 Aug 29. doi: 10.1111/bjh.16168. [Epub ahead of print]

PMID:
31468508
4.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] Review.

PMID:
31446199
5.

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Din L, Sheikh M, Kosaraju N, Smedby KE, Bernatsky S, Berndt SI, Skibola CF, Nieters A, Wang S, McKay JD, Cocco P, Maynadié M, Foretová L, Staines A, Mack TM, de Sanjosé S, Vyse TJ, Padyukov L, Monnereau A, Arslan AA, Moore A, Brooks-Wilson AR, Novak AJ, Glimelius B, Birmann BM, Link BK, Stewart C, Vajdic CM, Haioun C, Magnani C, Conti DV, Cox DG, Casabonne D, Albanes D, Kane E, Roman E, Muzi G, Salles G, Giles GG, Adami HO, Ghesquières H, De Vivo I, Clavel J, Cerhan JR, Spinelli JJ, Hofmann J, Vijai J, Curtin K, Costenbader KH, Onel K, Offit K, Teras LR, Morton L, Conde L, Miligi L, Melbye M, Ennas MG, Liebow M, Purdue MP, Glenn M, Southey MC, Din M, Rothman N, Camp NJ, Wong Doo N, Becker N, Pradhan N, Bracci PM, Boffetta P, Vineis P, Brennan P, Kraft P, Lan Q, Severson RK, Vermeulen RCH, Milne RL, Kaaks R, Travis RC, Weinstein SJ, Chanock SJ, Ansell SM, Slager SL, Zheng T, Zhang Y, Benavente Y, Taub Z, Madireddy L, Gourraud PA, Oksenberg JR, Cozen W, Hjalgrim H, Khankhanian P.

Genet Epidemiol. 2019 Aug 13. doi: 10.1002/gepi.22242. [Epub ahead of print]

PMID:
31407831
6.

An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Veeramani S, Blackwell SE, Thiel WH, Yang ZZ, Ansell SM, Giangrande PH, Weiner GJ.

Cancer Immunol Res. 2019 Sep;7(9):1511-1522. doi: 10.1158/2326-6066.CIR-18-0821. Epub 2019 Aug 5.

PMID:
31383650
7.

Impact of Concurrent Indolent Lymphoma on the Clinical Outcome of Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS.

Blood. 2019 Jul 26. pii: blood.2019000858. doi: 10.1182/blood.2019000858. [Epub ahead of print]

PMID:
31350266
8.

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS.

J Clin Oncol. 2019 Jul 20;37(21):1819-1827. doi: 10.1200/JCO.19.00014. Epub 2019 Jun 6.

PMID:
31170029
9.

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR.

Br J Haematol. 2019 Sep;186(6):820-828. doi: 10.1111/bjh.15997. Epub 2019 May 28.

PMID:
31135975
10.

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM.

J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.

PMID:
31112476
11.

Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, Kadin ME, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell SM, Feldman AL.

Blood. 2019 Jun 27;133(26):2776-2789. doi: 10.1182/blood.2019000626. Epub 2019 May 17.

PMID:
31101622
12.

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.

Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, Wellik L, Li Y, Krull J, Wenzl K, Novak AJ, Ansell SM, Bishop GA, Billadeau DD, Peng KW, Giles F, Schmitt DM, Witzig TE.

Blood. 2019 Jul 25;134(4):363-373. doi: 10.1182/blood.2018874560. Epub 2019 May 17.

PMID:
31101621
13.

The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma.

Ansell SM.

Cancer Immunol Res. 2019 May;7(5):696-700. doi: 10.1158/2326-6066.CIR-18-0890. Review.

PMID:
31043393
14.

Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas.

Zanwar S, Ansell SM.

Leuk Lymphoma. 2019 May 1:1-3. doi: 10.1080/10428194.2019.1608534. [Epub ahead of print] No abstract available.

PMID:
31039669
15.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML.

JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393.

PMID:
31021376
16.

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.

St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM, Nowakowski GS, Witzig TE.

Am J Hematol. 2019 Jul;94(7):786-793. doi: 10.1002/ajh.25493. Epub 2019 May 16.

PMID:
31006875
17.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.

PMID:
30990729
18.

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Markovic SN.

Leuk Res. 2019 Jun;81:1-9. doi: 10.1016/j.leukres.2019.03.009. Epub 2019 Apr 4.

PMID:
30978434
19.

Immunotherapy in Hodgkin Lymphoma: The Road Ahead.

Ansell SM.

Trends Immunol. 2019 May;40(5):380-386. doi: 10.1016/j.it.2019.03.003. Epub 2019 Apr 2. Review.

PMID:
30948348
20.

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.

Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11. No abstract available.

PMID:
30859549
21.

Two types of amyloidosis presenting in a single patient: a case series.

Sidiqi MH, McPhail ED, Theis JD, Dasari S, Vrana JA, Drosou ME, Leung N, Hayman S, Rajkumar SV, Warsame R, Ansell SM, Gertz MA, Grogan M, Dispenzieri A.

Blood Cancer J. 2019 Mar 5;9(3):30. doi: 10.1038/s41408-019-0193-9.

22.

Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.

Yang ZZ, Kim HJ, Villasboas JC, Price-Troska T, Jalali S, Wu H, Luchtel RA, Polley MC, Novak AJ, Ansell SM.

Cell Rep. 2019 Feb 19;26(8):2178-2193.e3. doi: 10.1016/j.celrep.2019.01.085.

23.

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.

Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM.

Blood Cancer J. 2019 Feb 19;9(3):22. doi: 10.1038/s41408-019-0185-9.

24.

Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

Ansell SM.

Leuk Lymphoma. 2019 May;60(5):1114-1115. doi: 10.1080/10428194.2018.1543887. Epub 2019 Jan 11. No abstract available.

PMID:
30632848
25.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.

J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.

26.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
27.

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.

Ansell SM.

Lancet Haematol. 2019 Jan;6(1):e2-e3. doi: 10.1016/S2352-3026(18)30210-2. No abstract available.

PMID:
30612711
28.

Tumor Microenvironment in T-Cell Lymphomas.

Bennani NN, Ansell SM.

Cancer Treat Res. 2019;176:69-82. doi: 10.1007/978-3-319-99716-2_3.

PMID:
30596213
29.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.

PMID:
30523119
30.

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR, Salles G.

J Clin Oncol. 2019 Jan 10;37(2):144-152. doi: 10.1200/JCO.18.00400. Epub 2018 Nov 27.

31.

Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.

Mackrides N, Chapman J, Larson MC, Ramos JC, Toomey N, Lin P, Maurer MJ, Rafaelle M, Tan Y, Ikpatt O, Syrbu S, Ansell SM, Habermann TM, Link BK, Feldman AL, Lossos IS, Cerhan JR, Vega F.

Am J Hematol. 2019 Feb;94(2):E62-E64. doi: 10.1002/ajh.25357. Epub 2018 Dec 5. No abstract available.

PMID:
30474261
32.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

33.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P.

Leukemia. 2019 Mar;33(3):790-794. doi: 10.1038/s41375-018-0286-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315235
34.

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.

McMaster ML, Berndt SI, Zhang J, Slager SL, Li SA, Vajdic CM, Smedby KE, Yan H, Birmann BM, Brown EE, Smith A, Kleinstern G, Fansler MM, Mayr C, Zhu B, Chung CC, Park JH, Burdette L, Hicks BD, Hutchinson A, Teras LR, Adami HO, Bracci PM, McKay J, Monnereau A, Link BK, Vermeulen RCH, Ansell SM, Maria A, Diver WR, Melbye M, Ojesina AI, Kraft P, Boffetta P, Clavel J, Giovannucci E, Besson CM, Canzian F, Travis RC, Vineis P, Weiderpass E, Montalvan R, Wang Z, Yeager M, Becker N, Benavente Y, Brennan P, Foretova L, Maynadie M, Nieters A, de Sanjose S, Staines A, Conde L, Riby J, Glimelius B, Hjalgrim H, Pradhan N, Feldman AL, Novak AJ, Lawrence C, Bassig BA, Lan Q, Zheng T, North KE, Tinker LF, Cozen W, Severson RK, Hofmann JN, Zhang Y, Jackson RD, Morton LM, Purdue MP, Chatterjee N, Offit K, Cerhan JR, Chanock SJ, Rothman N, Vijai J, Goldin LR, Skibola CF, Caporaso NE.

Nat Commun. 2018 Oct 10;9(1):4182. doi: 10.1038/s41467-018-06541-2.

35.

Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma.

Wenzl K, Manske MK, Sarangi V, Asmann YW, Greipp PT, Schoon HR, Braggio E, Maurer MJ, Feldman AL, Witzig TE, Slager SL, Ansell SM, Cerhan JR, Novak AJ.

Blood Cancer J. 2018 Oct 9;8(10):97. doi: 10.1038/s41408-018-0130-3.

36.

Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.

Ansell SM.

Cancer J. 2018 Sep/Oct;24(5):249-253. doi: 10.1097/PPO.0000000000000331. Review.

PMID:
30247261
37.

The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.

Jalali S, Ansell SM.

Hematol Oncol Clin North Am. 2018 Oct;32(5):777-786. doi: 10.1016/j.hoc.2018.05.005. Epub 2018 Jul 25. Review.

PMID:
30190017
38.

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.

Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ.

Clin Cancer Res. 2018 Dec 15;24(24):6408-6420. doi: 10.1158/1078-0432.CCR-17-3265. Epub 2018 Aug 20.

PMID:
30126942
39.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.

Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P.

Am J Hematol. 2018 Nov;93(11):1384-1393. doi: 10.1002/ajh.25254. Epub 2018 Oct 2.

PMID:
30121949
40.

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Jalali S, Price-Troska T, Paludo J, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Ansell SM.

Blood Adv. 2018 Aug 14;2(15):1985-1997. doi: 10.1182/bloodadvances.2018021113.

41.

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15.

PMID:
30104176
42.

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Møller MB, Nørgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL.

Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9.

PMID:
30093402
43.

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T.

Br J Haematol. 2018 Oct;183(2):196-211. doi: 10.1111/bjh.15515. Epub 2018 Aug 6.

PMID:
30080238
44.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

45.

Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?

Fang H, Kapoor P, Gonsalves WI, Frederick LA, Viswanatha D, Howard MT, He R, Morice WG 2nd, McPhail ED, Greipp PT, Ansell SM, Kyle RA, Gertz MA, Paludo J, Abeykoon J, King RL.

Am J Clin Pathol. 2018 Jul 3;150(2):168-176. doi: 10.1093/ajcp/aqy041.

PMID:
29868855
46.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1037-1046. doi: 10.2215/CJN.13041117. Epub 2018 May 30.

47.

Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, Habermann TM, Cerhan JR, Stapleton JT.

Br J Haematol. 2018 Sep;182(5):644-653. doi: 10.1111/bjh.15416. Epub 2018 May 29.

48.

PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.

He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL.

Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.

PMID:
29762141
49.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R.

Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.

50.

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides.

Price-Troska T, Yang ZZ, Diller D, Bayden A, Jarosinski M, Audie J, Ansell SM.

Invest New Drugs. 2019 Feb;37(1):9-16. doi: 10.1007/s10637-018-0606-9. Epub 2018 Apr 26.

PMID:
29696509

Supplemental Content

Loading ...
Support Center